Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT05535244
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Conditions
- Mature B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT05533775
- Locations
- 🇧🇷
Graacc-Grupo de Apoio ao adolescente e a crianca com cancer, Sao Paulo, São Paulo, Brazil
🇩🇰Rigshospitalet, København Ø, Denmark
🇫🇷Hôpital Pellegrin, Bordeaux, France
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
- Conditions
- NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
- Interventions
- Other: Placebo
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT05503264
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇨🇳The First Hospital of Jilin University, Changchun City, China
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
- Conditions
- Guillain-Barré Syndrome
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05494619
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- Conditions
- Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein OcclusionBranch Retinal Vein OcclusionCentral Retinal Vein OcclusionHemi-retinal Vein Occlusion
- Interventions
- Combination Product: Port Delivery System with Ranibizumab
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5000
- Registration Number
- NCT05476926
- Locations
- 🇨🇱
Red Salud UC Christus, Metropolitana, Chile
🇫🇷Alpes Retine, Montbonnot-Saint-Martin, France
🇫🇷Centre Des Arceaux, Montpellier, France
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT05459129
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇦🇺Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 93
- Registration Number
- NCT05419388
- Locations
- 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇨🇿Všeobecná fakultní nemocnice v Praze, Prague 2, Czechia
🇬🇷District General Hospital of Athens Laiko, Athens, Greece
Screening Study for Participants With Malignant Tumors
- Conditions
- Solid Tumors
- Interventions
- Other: Screening platform
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15000
- Registration Number
- NCT05419375
- Locations
- 🇬🇧
Royal Marsden Hospital, London, United Kingdom
🇬🇧Christie Hospital Nhs Trust, Manchester, United Kingdom
🇨🇷Clinica CIMCA, San José, Costa Rica
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
- Conditions
- Early Breast CancerLocally Advanced Breast CancerInflammatory Breast Cancer
- Interventions
- Drug: Investigator's Choice of ChemotherapyProcedure: SurgeryRadiation: Radiotherapy
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 347
- Registration Number
- NCT05415215
- Locations
- 🇦🇷
Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Argentina
🇧🇦Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
🇧🇷Hospital Araujo Jorge, Goiania, Goiás, Brazil
Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT05401565
- Locations
- 🇺🇸
CITrials, Inc., Bellflower, California, United States
🇺🇸ASCLEPES Research Centers, Panorama City, California, United States
🇺🇸Clinical Innovations, Inc, Santa Ana, California, United States